TPP medicines proposals would cost $205 million in one year
A study by health experts Deborah Gleeson, Ruth Lopert and Hazel Moir published in late December 2014 examines the potential costs for Australia of a proposal in the leaked intellectual property chapter of the Trans-Pacific Trade deal. which would extend test data protection for biologic medicines and delay the availability of cheaper generic versions. The study uses Medicare Australia expenditure data for the ten most expensive biologic drugs on the Pharmaceutical Benefits Scheme (PBS)to estimate the potential costs to Australian taxpayers of the proposed extension. Such an extension would have cost over $205 million in the year 2013-14 alone .